US/UK/Canada

Share

Quotes

We can now further support the needs of our customers with biologics projects by providing flexibility, leading technology solutions, commercial operations and an expanded footprint with two U.S. sites.
Jim Mullen, CEO of DPx Holdings
Today we are better positioned to add scale, new value chain capabilities and technologies, as well as expand our end-to-end service offerings to our customers as a global, comprehensive solution provider to the industry.
Jim Mullen, CEO of DPx
Pick a time period -
Tags ( Active)

Patheon to Highlight Solubility Solutions and Patheon OneSource™ at 2015 AAPS Annual Meeting and Exposition

Company to present 17 posters on a range of topics from validation of stability to process optimizationExperts from Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will present on a breadth of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held Oct. 25-29 in Orlando, Fla. Marshall Crew, vice president of global PDS scientific excellence, will deliver a presentation titled, “Improving Poor Solubility

Patheon to Highlight Flexible Capacity Solutions and Solubilization at CPhI/ICSE Worldwide 2015

Patheon’s Marshall Crew, Ph.D., and Joe Principe to present in the Speaker’s Corner on Oct. 14Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be on site at the 26th Annual CPhI/ICSE Worldwide conference from , Oct. 13 -  Oct. 15, in Madrid. Two noted Patheon experts will present at the Speaker’s Corner on Wednesday, Oct. 14. At noon, Marshall Crew, Ph.D. and vice president, global PDS scientific excellence, will discuss how to optimize solubilization strategies and

Patheon Unveils New Brand and Identity

“A Healthier World. Delivered.™” Reflects Company’s Focus on Helping Customers Deliver Life-changing MedicationsPatheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today unveiled its new brand identity, reflecting the company’s leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients. The new brand positioning centers around an updated brand promise based on the fundamental belief; the world would be a healthier place if tomorrow’s medicines were

ARDIAN ACQUIRES EXCLUSIVE SYNTHESIS (ES) AND MALEIC ANHYDRIDE INTERMEDIATES & SPECIALTIES (IM) BUSINESS FROM DPx HOLDINGS B.V.

Ardian, together with current management, to acquire agrochemicals (ES) and fine chemicals (IM) business activities of DPx Holdings B.V. to gain full independence, expand product portfolio and further international growthArdian, the independent private investment company, today announces the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities, based in Linz, Austria, of DPx Holdings B.V. The parties have agreed not to disclose details of the transaction. The completion of the transaction is still subject to approval by the

LIVIA Group acquires Patheon Facility in Capua, Italy

LIVIA Group, a German-based industrial holding, has entered into an agreement to acquire the Capua manufacturing facility and associated employees from Patheon, a leading global provider of outsourced contract development and manufacturing (CDMO) services for the pharma and biopharma industries. Capua, one of the world’s largest independent microbial fermentation-based manufacturing facilities with 1,400m³ fermentor capacity, represents an exceptional investment opportunity for LIVIA in the highly attractive market of enzymes and small molecules. “LIVIA Group is enthusiastic about

Patheon Announces Biologics Deal with Inhibrx

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has entered into a development contract with Inhibrx, abiologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions. As part of the agreement, Patheon will develop production processes at its Princeton, N.J., facility and will manufacture products at its Brisbane, Australia, location in support of a pipeline of future programs with Inhibrx. The initial

Patheon to Exhibit Biologics Services and Expertise at 2015 BIO International Convention

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programs at the BIO International Convention in Philadelphia, from Tuesday, June 16, to Wednesday, June 17.    Two of Patheon’s biologics rapid development and scale-up experts, Matt Caple, scientific director, cell culture development, and Tertia Dex, director, business development, will offer exclusive scientific

Patheon Files Registration For Initial Public Offering

Patheon, a leading global provider of outsourced pharmaceutical development and manufacturing services through its end-to-end integrated service offering,  today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering. The proposed offering will be

Patheon Scientist Dr. Marshall Crew Named to Medicine Maker Power List 2015

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that Dr. Marshall Crew, vice president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacture by the publication The Medicine Maker.  Dr. Crew, an elite scientist and expert in low-solubility drug formulation, was previously CEO and founder of Agere Pharmaceuticals, a CDMO specializing in oral bioavailability of insoluble molecules that was recently acquired by

Patheon to Sponsor Webinar on Assessing Stability for Shipment of API and Drug Products

Analytical development experts will address questions about regulatory requirements, and stability and shipping studies in a complimentary webinar this month sponsored by Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries. Hosted by Pharmaceutical Technology, a comprehensive information source for professionals in the global pharmaceutical manufacturing drug development community, the webinar “Stability Assessment for Shipment of API and Drug Products,” will provide guidance on

Patheon Expands Stability Testing Capabilities in Greenville, NC

Company Invests $3 million in Equipment and Talent in its Centralized Stability Testing LabPatheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, is investing more than $3 million to expand its Greenville, N.C. site’s stability testing capabilities. The expansion includes the addition of the most advanced automated systems and the assembly of a highly experienced scientific team to enhance its centralized stability lab offerings. Since 2011, more than 1,000 stability studies with

JLL/Delta Dutch Pledgeco B.V. Announces Pricing of its Private Placement of $550 Million 8.75% / 9.50% Senior PIK Toggle Notes due 2020

JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the pricing of the previously announced private offering of $550 million aggregate principal amount of its 8.75% / 9.50% Senior PIK Toggle Notes due 2020 (the “Notes”). The total size of the offering of the Notes has been increased from $500 million to $550 million. The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering. The

JLL/Delta Dutch Pledgeco B.V. Announces Offering of $500 Million Senior PIK Toggle Notes due 2020

JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior PIK Toggle Notes due 2020 (the “Notes”). The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering. The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the

Patheon Scientist to Give Keynote Address at Lyophilisation USA Conference

A top scientific expert at Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be the keynote speaker at this year's Lyophilisation USA Conference , Wednesday, April 29, through Thursday, April 30, at the Renaissance Woodbridge Hotel in Iselin, N.J. Ronald Pate, lyophilization development scientist, will present, "Cycle Development Basic

Patheon to Participate in Industry Panels and Feature Patheon OneSourceTM at INTERPHEX

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase its broad set of development and manufacturing services, and the company’s integrated offering at INTERPHEX in New York City from Tuesday, April 21, to Thursday, April 23. Company leaders will offer industry insights during key panel discussions sponsored by the Pharma and BioPharma Outsourcing Association. Franco Negron, senior vice president of drug product services in North America for Patheon, will

Patheon Closes Acquisition of IRIX Pharmaceuticals

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire IRIX Pharmaceuticals, a Florence, S.C.-headquartered  company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API) for drugs from early and late development, through commercial launch. With the acquisition, Patheon establishes a North American presence for comprehensive API development and manufacturing to address customers’ most

Patheon Closes Acquisition of Agere Pharmaceuticals

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving the absorption rate of medications (bioavailability). The company will become part of Patheon’s pharmaceutical development services unit and operate as a solubility center of excellence in Bend, Ore.

Patheon Leaders to Attend DCAT Week

Durham, N.C.  — (March 11, 2015) Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sector, will participate at DCAT Week 2015 in New York, March 16-19. Patheon recently announced two acquisitions in support of the company’s business strategy to enter into logical adjacencies and drive industry consolidation. Patheon offerings now include North American API development and manufacturing services with the addition of IRIX Pharmaceuticals and a solubility center of excellence with the

Patheon Expands Comprehensive Active Pharmaceutical Ingredient Services with Acquisition of IRIX Pharmaceuticals

Number One Provider of Pharmaceutical Development Services Establishes Strong API Presence in U.S.Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced it has reached a definitive agreement to acquire IRIX Pharmaceuticals, a company headquartered in Florence, S.C., that specializes in difficult to manufacture Active Pharmaceutical Ingredient (API) needs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the

Patheon Adds Complex Solubility Expertise with Acquisition of Agere

Number One Provider of Pharmaceutical Development Services to Establish Global Solubility Center of Excellence in Western United StatesPatheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has reached a definitive agreement to acquire Agere Pharmaceuticals, a privately held CDMO, headquartered in Bend, Ore., that specializes in improving the absorption rate of medications (bioavailability). Agere is a recognized leader in helping customers improve the delivery of their medications

Patheon to Host Strategy Seminar for Emerging Companies

Industry-leading experts will discuss key strategies for early product development at a seminar this month hosted by  Patheon ®, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The event “API Supply: Key Strategies for Creating Value in Early-Stage Development,” which looks to address challenges in API development and drug formulation for emerging companies will be held Thursday, March 19, at the Embassy Suites Airport-Waterfront in San Francisco from 11:30 a.m. to 3:30 p.m. Experts

Patheon Cincinnati Regional Operations Recognized for Green Business Initiatives

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, will be honored as a finalist for the Green Business Award by the Cincinnati Business Courier for its outstanding leadership in sustainable practices, at the Sixth Annual Green Business Awards Program on Thursday, March 5 at 5:30 p.m., at the Sharonville Convention Center in Cincinnati. Patheon is one of several organizations to be honored for sustainable buildings, practices, products and advocacy. “We are thrilled to be

Patheon to Present at 2015 J.P. Morgan Global High Yield and Leveraged Finance Conference

Patheon , a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced today that James C. Mullen, CEO, will present an update on the company’s financial standing at the J.P. Morgan Global High Yield and Leveraged Finance Conference at the Loews Miami Beach Hotel in Miami, on Monday, Feb. 23 at 4 p.m.

There are no items matching the current filter
There are no more items matching the current filter
Back to top